¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"senescent cell antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • protective antigen
    ¹æ¾îÇ׿ø
  • public antigen
    °øÀ¯Ç׿ø
  • particulate antigen
    ¹Ì¸³ÀÚÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • residual antigen
    ÀÜ·ùÇ׿ø
  • soluble antigen
    °¡¿ë¼ºÇ׿ø
  • somatic antigen
    ±ÕüÇ׿ø
  • species-specific antigen
    Á¾Æ¯ÀÌÇ׿ø
  • specific antigen
    ƯÀÌÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • self antigen
    ÀÚ°¡Ç׿ø
  • sequestered antigen
    ÀºÆóÇ׿ø, °Ý¸®Ç׿ø
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • residual antigen
    ÀÜ¿©Ç׿ø
  • self antigen
    ÀÚ±âÇ׿ø
  • sensitized antigen
    ¹Î°¨Ç׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • serologically defined antigen
    Ç÷ûÇÐÀû±ÔÁ¤Ç׿ø
  • soluble antigen
    ¼ö¿ë¼ºÇ׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • specific antigen
    ƯÀÌÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • thymus-dependent antigen
    °¡½¿»ùÀÇÁ¸Ç׿ø
  • thymus-independent antigen
    °¡½¿»ùºñÀÇÁ¸Ç׿ø
  • transplantation antigen
    À̽ÄÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • type specific antigen
    ÇüƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Rh(D) antigen
    Rh(D) Ç׿ø
  • Ro antigen
    RoÇ׿ø
  • Ro antigen
    Ro Ç׿ø
  • Roger antigen
    ·ÎÀúÇ׿ø
  • Scianna antigen
    ½Ã¾Æ³ªÇ׿ø
  • Sda antigen
    Sda Ç׿ø
  • Sp (Pr) antigen
    Sp(Pr) Ç׿ø
  • T dependent antigen
    TÀÇÁ¸¼ºÇ׿ø
  • Tac antigen
    Tac Ç׿ø
  • Thy-1 antigen
    Thy-1Ç׿ø
  • U antigen
    U Ç׿ø
  • V antigen
    V Ç׿ø
  • Vi antigen
    ViÇ׿ø.
  • Wright Antigen
    ¶óÀÌÆ®Ç׿ø
  • a antigen
    A Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antigen, Rh
    RhÇ׿ø
  • antigen, Thy-1
    Thy-1Ç׿ø
  • antigen, Vi
    ViÇ׿ø
  • antigen, capsular
    Çù¸·Ç׿ø
  • antigen, carcinoembryonic
    ¾ÏžÆÇ׿ø
  • antigen, colonization factor
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • antigen, complete
    ¿ÏÀüÇ׿ø
  • antigen, conjugated
    °áÇÕÇ׿ø
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • antigen, fetal
    žÆÇ׿ø
  • antigen, fimbrial
    ¼¶¸ðÇ׿ø
  • antigen, flagellar
    Æí¸ðÇ׿ø
  • antigen, hepatitis B core
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • antigen, hepatitis B surface
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • antigen, histocompatibility
    Á¶Á÷ÀûÇÕÇ׿ø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Ciliated cell
    ¼¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð¼¼Æ÷
  • Apex of cell
    ¼¼Æ÷²À´ë±â
    [¿¾ ¿ë¾î] ¼¼Æ÷÷
  • Cell membrane
    ¼¼Æ÷¸·
    [¿¾ ¿ë¾î] ¼¼Æ÷¸·
  • Base of cell
    ¼¼Æ÷¹Ù´Ú
    [¿¾ ¿ë¾î] ¼¼Æ÷Àú
  • Cell organelles
    ¼¼Æ÷¼Ò±â°ü
    [¿¾ ¿ë¾î] ¼¼Æ÷¼Ò±â°ü
  • Axis of cell
    ¼¼Æ÷Ãà
    [¿¾ ¿ë¾î] ¼¼Æ÷Ãà
  • Parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Follicular cell
    ¼ÒÆ÷¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¼¼Æ÷
  • Inner pillar cell
    ¼Ó±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁÖ¼¼Æ÷
  • Inner sustentacular cell
    ¼Ó¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁöÁÖ¼¼Æ÷
  • Inner cell mass (Embryoblast)
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»¼¼Æ÷±«
  • Inner cell mass [Embryoblast]
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»ºÎ¼¼Æ÷±«
  • Inner phalangeal cell
    ¼Ó¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ³»Áö»ó¼¼Æ÷
  • Medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁú³»ºÐºñ¼¼Æ÷
  • Inner hair cell
    ¼ÓÅм¼Æ÷
    [¿¾ ¿ë¾î] ³»À¯¸ð¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • cell hybridization
    ¼¼Æ÷(á¬øà) Æ¢±âÇü¼º(û¡à÷)
  • cell line
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • cell membrane
    ¼¼Æ÷¸· (á¬øàØ¯)
  • cell strain
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell wall
    ¼¼Æ÷º®(á¬øàÛú)
  • centrifuge cell
    ¿ø½ÉºÐ¸®½Ç(êÀãýÝÂ×îãø)
  • competent cell
    Àû°Ý¼¼Æ÷(îêÌ«á¬øà)
  • constitutive secretory cell
    ±¸¼º¼º ºÐºñ¼¼Æ÷(ϰà÷àõÝÂÝôá¬øà)
  • continuous cell line
    "Áö¼Ó¼¼Æ÷ÁÖ(ò¥áÙá¬øàñ»), (ÔÒ) established cell line"
  • COS cell
    COS ¼¼Æ÷(á¬øà)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • double-sector cell
    ÀÌÁß±¸È¹½Ç(ì£ñìÏ¡üñãø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
Th cell helper T cell(= T4 cell)
Ts cell suppressor T cell(= T8 cell)
BC Bachelor of Surgery [Lat. Baccal-aureus Chirurgiae]; back care; bactericidal concentration; basal ce...
DRBC denaturated red blood cell; dog red blood cell; donkey red blood cell
EC effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
M cell Mauthner cell
NK cell natural killer cell
P-cell Purkinje cell
TCRBCL T cell rich B cell lymphoma
B cell cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell lymphoma
    B ¼¼Æ÷ ¸²ÇÁÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾ Áß¿¡¼­ ¥ì¼â, DR Ç׿ø, Leu-10ÀÇ B ¸²ÇÁ±¸ Ç¥½ÃÀÚ°¡ Áõ¸íµÈ ¸²ÇÁÁ¾ÀÌ´Ù. Áõ¸íµÈ Ç¥½ÃÀÚ´Â °³°³ÀÇ Áõ·Ê¿¡ µû¶ó ´Ù¸£°í ¥ì+, DR+ Leu-10+ÀÇ ÀüÇüÀûÀÎ ¿¹·ÎºÎÅÍ DR ³»Áö Leu-10¸¸ÀÌ ¾ç¼ºÀÎ Áõ·Ê¿¡ À̸£±â±îÁö ±× º¯È­´Â ´Ù¾çÇÏ´Ù. ÇüÅÂÀûÀÎ ºÐ·ù¿¡ ÀÇÇÑ °áÀý¼º ¸²ÇÁÁ¾, ¸²ÇÁÇüÁú ¼¼Æ÷¼º ¸²ÇÁÁ¾, ¹èÁ᫐ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾ µîÀÌ B¼¼Æ÷ ¸²ÇÁÁ¾¿¡ ¼ÓÇÑ´Ù.
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • B cell tolerance
    B ¼¼Æ÷ ³»¼º
    ¸é¿ªÇÐÀû ³»¼º »óÅ´ T ¼¼Æ÷¿¡µµ B ¼¼Æ÷¿¡µµ ¹ß»ý ¼ö ÀÖÁö¸¸ B ¼¼Æ÷ÀÇ ³»¼º »óÅ´ T ¼¼Æ÷¿¡ ºñÇÏ¿© ¹ß»ýÇϱⰡ ¾î·Æ´Ù. B ¼¼Æ÷¸¦ ³»¼º »óÅ·ΠÇÏ·Á¸é ÀϹÝÀûÀ¸·Î ´ë·®ÀÇ Ç׿øÀÌ ÇÊ¿äÇϰí Ç׿ø Åõ¿© ÈÄ¿¡ ³»¼º »óÅ·Πµé¾î°¡´Â µ¥µµ T ¼¼Æ÷º¸´Ù ¿À·£ ½Ã°£ÀÌ °É¸®°í ÀÏ´Ü ³»¼º »óÅ·Πµé¾î°¡µµ Áö¼Ó½Ã°£ÀÌ Âª°í °ð ÇØÁ¦µÇ¾î ¹ö¸°´Ù.
  • band cell
    ¶ì ¼¼Æ÷
  • basal cell
    ±âÀú ¼¼Æ÷, ±âÃÊ ¼¼Æ÷
    Ç¥ÇÇ ±âÀúÃþ¿¡ Á¸ÀçÇÏ´Â Ãʱâ ÄÉ¶óÆ¾ ¼¼Æ÷¸¦ ÀÏÄ´ À̸§. Æ÷À¯·ù Á¤¼ÒÀÇ ¼¼Á¤°ü ¼Ó¿¡¼­ ¿ÜÃø ±âÀú¸·¿¡ Á¢ÇÏ¿© »êÀçÇØ ÀÖ´Â ´ëÇü ¼¼Æ÷. ¼¼¸£Å縮 ¼¼Æ÷
  • basal cell adenocarainoma
    ±âÀú ¼¼Æ÷ ¼±¾Ï
    ¸Å¿ì µå¹°°í ±âÀú ¼¼Æ÷ ¼±Á¾ÀÇ ¾Ç¼ºÀÌ´Ù. ¿Ü°úÀû ÀýÁ¦ ½Ã ¿¹Èİ¡ ÁÁ´Ù.
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
hepatitis B core antigen <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections.
(05 Mar 2000)
hepatitis B e antigen (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious.
(05 Mar 2000)
hepatitis B surface antigen <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test.
(27 Sep 1997)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
heterogeneic antigen An antigen or antigenic determinant which is found in different tissues in more than one species.
(05 Mar 2000)
heterogenetic antigen An antigen which is possessed by a variety of different phylogenetically unrelated species; e.g., the various organ-or tissue-specific antigen's, the alpha-and beta-crystalline protein of the lens of the eye, and Forssman antigen.
Synonym: heterophil antigen.
(05 Mar 2000)
heterogenic enterobacterial antigen Cross reacting antigen (epitope), a common antigen that occurs in 2 or more different molecules/organisms.
Synonym: heterogenic enterobacterial antigen.
(05 Mar 2000)
heterophil antigen An antigen which is possessed by a variety of different phylogenetically unrelated species; e.g., the various organ-or tissue-specific antigen's, the alpha-and beta-crystalline protein of the lens of the eye, and Forssman antigen.
Synonym: heterophil antigen.
(05 Mar 2000)
heterophile antigen An antigen or antigenic determinant which is found in different tissues in more than one species.
(05 Mar 2000)
Xg antigen xg blood group
histocompatibility antigen <immunology> A set of plasmalemmal glycoproteins on the surface of all nucleated cells that are crucial for T-cell recognition of antigens. Particularly the HLA system in humans and the H2 system in mice. They are the major antigens responsible for tissue recognition. For this reason, they are of prime importance in determining compatible organ donors for a specific transplantation procedure. Each person has unique HLA antigens. Some HLA antigens have been identified to be correlated with the presence of certain autoimmune diseases. One of these is the HLA-B27 site. Approximately 85% of patients with ankylosing spondylitis and Reiter's syndrome will have the HLA-B27 antigen present on the leukocytes.
There are two classes of histocompatibility antigens:
1. Class I, histocompatibility antigens composed of two glycosylated subunits, a heavy chain of 44 kD and beta2 microglobulin (12 kD). The heavy chain may be coded by K, D or L genes of mouse H2 and A, B or C genes of human HLA complex. Class I antigens are important in T-cell killing and are recognised in conjunction with the foreign cell surface antigens MHC restriction).
2. Class II antigens, heterodimeric histocompatibility antigens composed of alpha (32 kD) and beta (28 kD) chains. Found mostly on B lymphocytes, macrophages and accessory cells. The response of T helper cells requires that the foreign antigen is presented in conjunction with the appropriate Class II antigens. (Murine H2 Ia antigens and human HLA DR antigens are Class II).
(14 Oct 1997)
HLA-a1 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. Individuals bearing this allele are more susceptible to hodgkin's disease. HLA-a1 is in linkage disequilibrium with HLA-b8 and HLA-dr3.
(12 Dec 1998)
HLA-a2 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The HLA-a2 antigen is associated with recognition of the influenza a virus.
(12 Dec 1998)
HLA-a3 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The allele occurs with increased frequency in individuals with idiopathic haemochromatosis. HLA-a3 is in linkage disequilibrium with HLA-b7 and HLA-dr2.
(12 Dec 1998)
HLA-b27 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is strongly associated with acute anterior uveitis, ankylosing spondylitis, and reiter's disease.
Increased frequency of antigen in: ankylosing spondylitis (90%), Reiter syndrome (90%), enteropathic arthritis (75%), psoriatic arthritis (60%) normal frequency: white: 8%, black: 4%
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á